Gefurulimab

DB18928InvestigationalProtein Based Therapies

Gefurulimab is under investigation in clinical trial NCT05556096 (Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis).

Mechanism
Curator reviewed
Also known as
IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN SERUM ALBUMIN) (HUMAN-LAMA GLAMA MONOCLONAL ALXN1720 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (SYNTHETIC 15 AMINO-ACID) FUSION PROTEIN WITH ANTI-(HUMAN COMPLEMENT C5) (HUMAN-LAMA GLAMA MONOCLO
Code names
ALXN-1720

Resolves to

Compound
UNII6PWU78BV6CCAS2456407-94-4
Targets
P01031C5

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Gefurulimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In